Altimmune, Inc.
ALT· Nasdaq
Released May 9, 2024, before the open
10-Q filed May 9, 2024, 39 days after period end · 0001326190-24-000019
| Metric | Q1 2024 | Q1 2023 | Q1 2022 | Q1 2021 |
|---|---|---|---|---|
| Revenue | $5.00K | $21.00K | $32.00K | $838.00K |
| Net Income | -$24.39M | -$20.07M | -$19.43M | -$14.86M |
| EPS Diluted |
Altimmune, Inc. · CIK 1326190 · Engraved from SEC EDGAR
| -$0.34 |
| -$0.40 |
| -$0.44 |
| -$0.38 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.